Mucosolvan Hustensaft-Portionsbeutel (Ambroxol Hydrochloride)

Ambroxol stimulates serous cells in the airway to produce thinner, more watery mucus and reduces the viscosity of existing sputum. This enhances mucociliary transport, making it easier to expectorate secretions and improving airway ventilation.

The appropriate dose of Mucosolvan is set by the prescribing healthcare professional based on the patient’s age, weight, severity of symptoms, and renal function. No fixed regimen is provided here; the prescriber tailors therapy to individual needs.

Safety data for Ambroxol in pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit outweighs any possible risk, and only under medical supervision. Women who are pregnant or nursing should discuss use with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ambroxol, the active ingredient in Mucosolvan, is a well‑studied mucolytic that both thins mucus and stimulates its secretion, offering a dual mechanism. Compared with agents such as acetylcysteine, Ambroxol often has a more favorable taste profile and a lower incidence of bronchospasm.

Store Mucosolvan Hustensaft‑Portionsbeutel at ambient temperature, below 25 °C. Keep the sachets in their original packaging, protect them from moisture, direct sunlight and extreme heat to maintain product stability.

The oral solution is supplied in single‑use portion sachets. The content is typically dissolved in a small amount of water or taken directly as instructed by the healthcare provider. Administration is oral, and the patient should follow the prescriber’s directions regarding frequency.

Serious adverse events, although rare, include allergic reactions such as rash, angioedema, and severe skin disorders like Stevens‑Johnson syndrome. Hepatic enzyme elevations have also been reported. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, or extensive skin eruptions.

Mucosolvan should be avoided in individuals with a known hypersensitivity to Ambroxol Hydrochloride or any of the excipients in the formulation. It is also contraindicated in patients who have experienced severe allergic reactions to other mucolytic agents.